9 Meters Biopharma, Inc. to Present Data on Therapeutic Candidate in Short Bowel Syndrome at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
9 Meters Biopharma (NASDAQ:NMTR) will present a poster on its therapeutic candidate vurolenatide for short bowel syndrome at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting. The event takes place from October 22-27, 2021 in Las Vegas, Nevada. The poster presentation, led by Patrick H. Griffin, M.D., will occur on October 26, with the poster on display from 10:30 a.m. to 4 p.m. PT. The company will also exhibit at booth 843 during the meeting.
- None.
- None.
RALEIGH, NC / ACCESSWIRE / October 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today that the company will deliver a poster presentation highlighting vurolenatide, 9 Meters' therapeutic candidate in short bowel syndrome, and will host a booth exhibit at the in-person component of the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting, held in a hybrid format both virtually and in Las Vegas, Nevada on October 22 - 27, 2021.
Participation Details:
Poster
Poster number: P3006
Location: Mandalay Bay Convention Center, Shoreline Exhibit Hall
Presenter: Patrick H. Griffin, M.D., 9 Meters' chief medical officer
Presentation date: Tuesday, October 26, 2021
Poster on display: 10:30 a.m. - 4 p.m. PT
Presenter at poster: 1 p.m. - 2:15 p.m. PT
Booth
Booth number: 843
Location: Mandalay Bay Convention Center, Shoreline Exhibit Hall
Hall hours: Sunday, October 24, 2021: 3 p.m. - 7 p.m. PT
Monday, October 25, 2021: 10 a.m. - 4:45 p.m. PT
Tuesday, October 26, 2021: 10 a.m. - 4:30 p.m. PT
About 9 Meters Biopharma
9 Meters Biopharma, Inc. is a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology. The Company is advancing vurolenatide, a proprietary Phase 2 long-acting GLP-1 agonist, for short bowel syndrome (SBS); larazotide, a Phase 3 tight junction regulator in non-responsive celiac disease; and several other early-stage assets.
For more information, please visit www.9meters.com or follow 9 Meters on Twitter and LinkedIn.
Forward-looking Statements
This press release includes forward-looking statements based upon the Company's current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, anticipated milestones and any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: reliance on collaborators; risks associated with acquiring and developing additional compounds; uncertainties associated with the clinical development and regulatory approval of product candidates; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; the impact of COVID-19 on our operations, enrollment in and timing of clinical trials; and risks related to the inability of the Company to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements because of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, Form 10-Q for the quarter ended June 30, 2021, and in other filings that the Company has made and future filings the Company will make with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Corporate Contacts:
Edward J. Sitar
Chief Financial Officer
9 Meters Biopharma, Inc.
investor-relations@9meters.com
www.9meters.com
Media Contact:
Veronica Eames
LifeSci Communications, LLC
veames@lifescicomms.com
203-942-4626
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577
SOURCE: 9 Meters Biopharma, Inc.
View source version on accesswire.com:
https://www.accesswire.com/668558/9-Meters-Biopharma-Inc-to-Present-Data-on-Therapeutic-Candidate-in-Short-Bowel-Syndrome-at-the-American-College-of-Gastroenterology-ACG-2021-Annual-Scientific-Meeting
FAQ
When will 9 Meters Biopharma present at the ACG Annual Scientific Meeting?
What is vurolenatide and its significance?
Where will the ACG Annual Scientific Meeting be held?
What time will the poster be displayed?
What is the booth number for 9 Meters Biopharma at the ACG event?
Who is presenting the poster for 9 Meters Biopharma?
